Transcript Ronald van Vollenhoven, Melinda Mild

Ongoing and planned studies at ClinTRID
Project
Funding
Description (number of subjects)
Main investigator, Coordinator, Key persons, Contact
Status
Initiated
Expected to be completed
1. NORD-STAR
• Swedish Medical Research
• SLL
• Medication provided by BMS and UCB Pharma
• Unrestricted funds
Nordic randomized clinical trial in early RA. Initial 4-way
randomization (conventional vs. 3 biologics);
re-randomization for patients in remission to immediate vs.
delayed step-down therapy. Appr. 3 year duration per patient
(800 patients)
Ronald van Vollenhoven, Maria Seddighzadeh, Camilla Gustafsson, Eleonore Nilsson,
Peter Westerling, Melinda Mild, Nancy Vivar
[email protected]
First patient in IV/2012
2010
2017
2. IRBIS-retrospective
Unrestricted funds
International registry (>400)
Ronald van Vollenhoven, Melinda Mild, Anna Andersson,
[email protected]
Retrospectively >400 patients have been
registered; manuscript in preparation
2010
2020
3. IRBIS-prospective
GSK
Unrestricted funds
International prospective registry (Projected:2000)
Ronald van Vollenhoven, Melinda Mild, Anna Andersson, Noémi Györi, Sara Linder
[email protected]
The prospective registry was opened on
March 10, 2012; 52 patients included
2012
2025
European registry collaboration (>3000)
Katerina Chatzidionysiou
[email protected]
Data on ca 3000 rituximab treated
patients has been processed,
3 published articles, >6 presentations at
EULAR and ACR
2009
2019
In preparation
2012
2018
4. CERERRA
Unrestricted funds
5. RING trial
(rituximab in SLE)
Unrestricted funds
European randomized clinical trial with rituximab
in refractory SLE nephritis (200)
Ronald van Vollenhoven, Fred Houssiau, Peter Westerling, Adrian Levitsky,
Noémi Györi
[email protected]
6. Rituxilup
(rituximab in SLE)
ARUK
Unrestricted funds
European randomized clinical trial with rituximab
in new-onset SLE nephritis (200)
Ronald van Vollenhoven, Liz Lightstone, Peter Westerling, Adrian Levitsky,
Noémi Györi
[email protected]
In preparation
2012
2018
7. TREES
(anti-CD20 in SLE)
ARUK
Unrestricted funds
European randomized clinical trial with anti-CD20
in non-renal SLE (200)
Ronald van Vollenhoven, Ian Bruce, Peter Westerling, Adrian Levitsky
[email protected]
In preparation
2012
2018
8. ULTRASOUND:
Evaluation of diagnostic utility
according to Bayes
Unrestricted funds
Swedish Collaboration Project (100)
Hamed Rezaei, Yogan Kisten, Noémi Györi
[email protected]
Ca 80 of 100 patients included;
Poster EULAR 2013
2010
2013
9. MUSCARA:
Ultrasound support in choice
of therapy
Abbott
Prospective Swedish collaborative project (120)
Hamed Rezaei, Peter Westerling, Erik af Klint, Yogan Kisten, Noémi Györi
[email protected]
First patient in study February 2013
2012
2015
Feasibility study of new diagnostic tool
Erik af Klint, Yogan Kisten, Noémi Györi, Anna Karlsson, Carolina Romanus
[email protected]
2012
2014
5-year clinical, radiological, and health-economic
evaluation
Ronald van Vollenhoven, Melinda Mild, Jonas Ericsson, Martin Neovius,
Margareta Lindmark, Heather Miller, Adrian Levitsky, Noémi Györi, Nancy Vivar
[email protected]
In preparation
2013
2015
Biomarkers in early RA, in collaboration with Crescendo
(487)
Karen Hambardzumyan, Melinda Mild, Adrian Levitsky, Nancy Vivar
[email protected]
Two poster presentations at
EULAR 2013
2011
2014
International GWAS collaboration through Mayo Clinic
Ronald van Vollenhoven, Melinda Mild, Karen Hambardzumyan,
Saedis Saevarsdottir, Leonid Padyukov
[email protected]
DNA sent to Mayo Clinic,
analyses in progress
2012
2013
Predictive x-ray progression in early RA
Ronald van Vollenhoven, Melinda Mild, Adrian Levitsky
[email protected]
Poster at EULAR 2013
2011
2013
Adipokines in early RA, extension study
Ronald van Vollenhoven, Kerstin Brismar, Melinda Mild, Adrian Levitsky,
Karen Hambardzumyan, Anna Andersson, Inga-Lill Engvall, Nancy Vivar
[email protected]
Adiponektin and leptin results available,
IGF-1 pending. Analyses ongoing
2012
2013
Study of ACPA fine specificity as prediction marker
Saedis Saevarsdottir, Melinda Mild, Alf Kastbom, Anna Andersson, Adrian Levitsky
[email protected]
Ongoing
2012
2013
Collaboration with Prof. Maria Bokarewa (Göteborg)
Ronald van Vollenhoven, Maria Bokarewa, Melinda Mild,
Karen Hambardzumyan, Adrian Levitsky
[email protected]
Samples sent to Göteborg
2013
2013
Clinical chart review project (180)
Cecilia Lourdudoss, Sanaa Jamil
[email protected]
Completed
Presented at CORA 2013;
manuscript in preparation
2011
2012
Enrollment to start during spring of 2013
2011
2013
10. RHEUMASCAN:
(fluorescence optical imaging)
11. SWEFOT 5-year follow-up
12. SWEFOT Biomarkers
Unrestricted funds
13. SWEFOT PAMERA
14. SWEFOT POPERA
15. SWEFOT Adipokines
16. SWEFOT
ACPA fine specificity
Unrestricted funds
Unrestricted funds
Unrestricted funds
17. SWEFOT Survivin
18. CELLCEPT
in SLE and vasculitis
Unrestricted funds
19. HCQ compliance
Unrestricted funds
International study (300)
External, Cecilia Lourdudoss, Noémi Györi
[email protected]
20. Nutrition and therapy
results in RA and SLE
Unrestricted funds
Registry study; PhD project (2000)
Cecilia Lourdudoss
[email protected]
Ongoing
2012
2015
Clinical Trial (32)
Ronald van Vollenhoven, Katerina Chatzidionysiou, Eleonore Nilsson
[email protected]
Trial completed
Results presented at ACR 2012;
manuscript in preparation
2008
2013
Clinical Trial (90)
Ronald van Vollenhoven, Lara Dani, Seija Johansson
[email protected]
Trial completed
Results presented at ACR2012;
manuscript in preparation
2008
2013
Certolizumab in RA, ARTIS registry study (400)
Katerina.Chatzidionysiou
[email protected]
Abstract EULAR 2012,
Manuscript in preparation
2011
2013
Treatment sequences with biologic drugs in RA (~2000)
Katerina.Chatzidionysiou
[email protected]
First data at ACR 2011
Manuscript in preparation
2010
2012
European registries collaboration (2000)
Katerina Chatzidionysiou, Cem Gabay
[email protected]
In preparation
2012
2022
26. Review health-economic
registry studies in Nordic
countries
Literature review; PhD project
Heather Miller
[email protected]
Ongoing
2012
2013
27. Health-economic studies of
data from SWEFOT,
DOSERA and other trials
Health-economic data analysis and modeling; PhD project
Heather Miller
[email protected]
Planning stage
2013
2015
28. Ultrasound in Psoriasis
Pilot study
Ronald van Vollenhoven, Mona Ståhle, Yogan Kisten, Hamed Rezaei, Noémi Györi
[email protected]
Planning stage
2013
2014
29. Request study
Survey of infliximab treated patients
Sanaa Jamil, Jenny Riazzoli
Study completed . Analyses ongoing
2008
2013
30. Rituximab
long-term follow up
Follow-up of rituximab treated patients with SLE
Sara Linder, Iva Gunnarsson, Noémi Györi
[email protected]
Planning stage
2013
2014
31. Rituximab B-cell markers
Sara Linder, Noémi Györi, Vivi Malmström, Louise Berg
Planning stage
2013
2014
32. PDA study
Ronald van Vollenhoven
[email protected]
Study completed. Some analyses and
publication remaining.
2008
2013
21. ADMIRE
22. DOSERA
23. ARTIS CZP
24. ARTIS
Treatment sequences
25. TOCERRA
Abbott
Pfizer
UCB Pharma
Unrestricted funds
Roche
Study of PDA use in adalimumab treated patients